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A B S T R A C T   
Background: The prevalence of depression is higher among those with diabetes than in the general population. 
The Patient Health Questionnaire (PHQ-9) is commonly used to assess depression in people with diabetes, but 
measurement invariance of the PHQ-9 across groups of people with and without diabetes has not yet been 
investigated. 
Methods: Data from three independent cohorts from the USA (n=1,886 with diabetes, n=4,153 without diabetes), 
Quebec, Canada (n= 800 with diabetes, n= 2,411 without diabetes), and the UK (n=4,981 with diabetes, 
n=145,570 without diabetes), were used to examine measurement invariance between adults with and without 
diabetes. A series of multiple group confirmatory factor analyses were performed, with increasingly stringent 
model constraints applied to assess configural, equal thresholds, and equal thresholds and loadings invariance, 
respectively. One-factor and two-factor (somatic and cognitive-affective items) models were examined. 
Results: Results demonstrated that the most stringent models, testing equal loadings and thresholds, had satis-
factory model fit in the three cohorts for one-factor models (RMSEA = .063 or below and CFI = .978 or above) 
and two-factor models (RMSEA = .042 or below and CFI = .989 or above). 
Limitations: Data were from Western countries only and we could not distinguish between type of diabetes. 
Conclusions:  Results provide support for measurement invariance between groups of people with and without 
diabetes, using either a one-factor or a two-factor model. While the two-factor solution has a slightly better fit, 
the one-factor solution is more parsimonious. Depending on research or clinical needs, both factor structures can 
be used.   
1. Introduction 
People with diabetes have an increased risk of developing clinical 
and sub-clinical depression (Nouwen et al., 2010; Albertorio et al., 
2017). Because depression in diabetes has been associated with adverse 
consequences, including a higher risk of diabetes complications (Nou-
wen et al., 2019), mortality (van Dooren et al., 2013), and cognitive 
decline (Schmitz et al., 2018), the regular screening of depressive 
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symptoms among people with diabetes has been suggested to clinicians 
(Young-Hyman et al., 2016). Originally developed in the US to screen for 
depressive disorders in primary care (Spitzer et al., 2001), the Patient 
Health Questionnaire-9 (PHQ-9) has become a widely used self-report 
depression screening tool for clinicians and researchers across the 
world. The scale is based on DSM-IV diagnostic criteria (Diagnostic and 
Statistical Manual of Mental Disorders, fourth edition; DSMIV; American 
Psychiatric Association, 1994) and assesses the affective, cognitive, and 
somatic symptoms of depression. 
Despite the PHQ-9 having been developed and validated for use in 
primary care (Kroenke et al., 2010; Sung et al., 2013), the PHQ-9 is also 
commonly used in samples of people with diabetes. Some studies have 
provided psychometric support for use of the PHQ-9 in people with type 
1 and type 2 diabetes. For instance, the PHQ-9 has been shown to have 
good internal consistency and convergent validity in people with dia-
betes (Janssen et al., 2016). However, questions remain regarding 
measurement invariance and the PHQ-9’s underlying factor structure, 
using one or two factors, in diabetes samples (Boothroyd et al, 2019). In 
primary care samples, studies relying on exploratory factor analysis tend 
to report a single factor solution (i.e., all items loading on the same 
single factor) (e.g. Cameron et al., 2008; Dum, et al., 2008, Hanssen 
et al., 2009; Huang et al., 2006), while studies using confirmatory factor 
analysis have found that a two-factor solution, with one factor reflecting 
the somatic items of the PHQ-9 and the other factor the 
cognitive-affective items, has better model fit (Beard et al., 2016; Chil-
cot et al., 2013; Petersen et al., 2015). The only study examining the 
PHQ-9 factor structure in people with diabetes, to our knowledge, found 
a better fit for a two-factor solution than the one-factor solution both in 
people with and without diabetes (Janssen et al., 2016). 
Measurement invariance can be used to compare the stability of a 
scale’s factor structure between groups (van de Schoot et al., 2015). A 
number of studies have shown that the PHQ-9 is scale or measurement 
invariant, that is, that the PHQ-9 items measure the same underlying 
factor structure across different groups and settings for both the one- and 
two-factor models. Specifically, invariance has been shown for different 
demographic (age, sex, education level and marital status; 
González-Blanch et al., 2018; Leung et al., 2020; Harry et al., 2019; 
Petersen et al., 2015; Villarreal-Zegarra et al., 2019), cross-cultural 
(Keum et al., 2018; Miranda and Scopetta, 2018), US student pop-
ulations; Galenkamp et al, 2017), Netherlands Dutch and ethnic mi-
norities (Arthurs et al., 2012; Merz et al., 2011), and patient groups (e.g. 
primary and secondary care) in the US and elsewhere. However, only 
one study reported assessing whether the PHQ-9 is scale invariant be-
tween people with and without diabetes, but no detailed statistical in-
formation on measurement invariance testing was provided. Research 
demonstrating measurement invariance is needed, as it currently re-
mains unclear whether the meaning of the PHQ-9 items is similar for 
people with and without diabetes. This is particularly relevant for a scale 
assessing depressive symptoms in people with diabetes, given the 
overlap between the somatic symptoms of depression (e.g. trouble fall-
ing/staying asleep, sleeping too much; feeling tired or having little en-
ergy; poor appetite or overeating) with those of diabetes (Harding et al., 
2019; McDade & Watson, 2011; Roy et al., 2012). 
Taken together, depression is a common comorbidity of diabetes that 
is often assessed in research and clinical practice using the PHQ-9. 
However, the PHQ-9 has not yet been validated in terms of measure-
ment invariance in this population. Therefore, the aim of this study was 
to first determine whether the PHQ-9 is measurement invariant between 
people with and without diabetes, and second, whether a one-factor or a 
two-factor was a better fit for diabetes samples, using three large data 
sets, namely the National Health and Nutrition Examination Survey 
(NHANES; USA), the Emotional Well-Being, Metabolic Factors and 
Health Status (EMHS) study and the Health, Inflammation, and 
Depression (HID) studies (Quebec, Canada), and the UK-Biobank (UK). 
2. Methods 
2.1. Samples 
Participants were from three data banks, namely the US NHANES 
2009-2014, the EMHS-HID from Canada, and the UK-Biobank. 
NHANES-USA 
2.1.1. Study design 
Data source—The National Health and Nutrition Examination Survey 
(NHANES) is a multipurpose cross-sectional health survey that measures 
the health and nutritional status of the civilian noninstitutionalized U.S. 
population. NHANES uses a complex survey stratified multistage, 
probability cluster design to select a representative sample of the pop-
ulation. In the U.S., the NHANES is the only national health survey that 
contains a dual protocol for the collection of self-report health infor-
mation and clinical, physical examination, and laboratory. The data 
collection is systematically achieved, allowing the identification of both 
diagnosed and undiagnosed health conditions (Boltri et al., 2005). 
NHANES data collection is completed in two phases. The first phase 
is a face-to-face interview in the participant’s household. The second 
phase consists of a series of private interviews, and physical and labo-
ratory examinations held in a mobile examination center (MEC). Both 
the household and MEC interviews are performed using a standard 
protocol with trained staff and recorded using computer-assisted per-
sonal interviewing (CAPI) protocols. NHANES data collection protocol 
has been approved by the National Center for Health Statistics Research 
Ethics Review Board. All the participants provided written informed 
consent. More information about NHANES collection protocols can be 
found elsewhere (National Health and Nutrition Examination Survey, 
2013, 2014). 
Analyses were performed using NHANES public-use data files. 
NHANES data files are based on an independent two-year cycle. Each 
data cycle contains its respective complex survey elements such as 
weight, primary sample unit, and strata to conduct extrapolation to the 
general non-institutionalized adult population. For the development of 
an analytical study, we combined three NHANES cycles to increase 
sample size, subsequently increasing the statistical power, and precision 
of the subdomain of diabetes (National Health and Nutrition Examina-
tion Survey, 2011). Following this strategy, three NHANES data cycles 
were merged for this study (i.e., 2009–2010, 2011–2012, and 
2013-2014 (National Health and Nutrition Examination Survey 2013)). 
For the present study, a total of 8,221 eligible adults ages 20 and 
older who visited the MEC and provided complete case data on diabetes 
and depression were selected. The PHQ-9 was administered by trained 
interviewers. Of those eligible, 1,886 participants self-reported having a 
diagnosis of diabetes and 4,153 participants self-reported never having 
received a diagnosis of diabetes. Participants who had diabetes as 
confirmed by a positive lab test (glucose and HA1c) but were unaware of 
having the condition (n = 2,182) were excluded from the analysis. 
Diabetes status in NHANES was based on self-reported physician 
diagnosis. Physician-diagnosed diabetes was obtained during the 
household interview. Women who reported having diabetes only during 
pregnancy were excluded from the sample. For the current study, sample 
weighting was not included in the invariance analysis since we aimed to 
study the measurement invariance and not derive non-institutionalized 
population estimates. 
EMHS-HID - Canada 
The EMHS and HID cohorts were combined for use in the present 
study to examine people with (HID) and without (EMHS) self-reported 
diabetes. Both samples were recruited from the original CARTaGENE 
study (www.cartagene.qc.ca), a large health survey of 20,004 French- 
and English-speaking residents of the Canadian province of Quebec 
between the ages of 40 and 69 years in 2009-2010 (Awadalla et al., 
2013). The principal aim of EMHS study was to examine the combined 
role of metabolic dysregulations and depressive symptoms in the risk of 
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type 2 diabetes (Schmitz et al., 2016). The principal aim of the HID study 
was to examine the role systemic inflammation in depression among 
people with diabetes. The EMHS and HID study procedures were 
approved by the Douglas Mental Health University Institute Ethics 
Board and the St Justine Hospital Research Ethics Board. 
A total of 2525 participants without diabetes at baseline from the 
CARTaGENE study participated in the EMHS follow-up in 2014-2015, 
and a total of 719 participants with diabetes from the CARTaGENE 
study participated in the HID follow-up in 2017. There were 87 partic-
ipants that did not have diabetes at the CARTaGENE baseline assessment 
but developed diabetes by the EMHS assessment, and they were thus 
included the diabetes sample for the present analyses. For the EMHS 
study, individuals with depressive symptoms and metabolic factors were 
oversampled. For the HID study, individuals with depressive symptoms 
were oversampled. The original CARTaGENE study collected survey 
information on depressive symptoms, lifestyle, and demographic infor-
mation, as well as health-related information, in addition to the 
collection of blood samples. CARTaGENE participants who participated 
in EMHS and HID completed a phone interview 5 years and 7 years, 
respectively, following the initial CARTaGENE assessment. These 
follow-up studies included the administration of the PHQ-9, used in the 
present study’s analyses. Data were collected by CAPI. 
Diabetes was assessed by self-report based on a diagnosis of diabetes 
made by a physician (EMHS) or by either a self-reported diagnosis of 
diabetes or HbA1c levels equal to or above 6.5 during the CARTaGENE 
baseline assessment (HID). Demographic variables were assessed by self- 
report. 
For the present study, a total of 2,411 EMHS participants without 
diabetes and 800 HID participants with diabetes were included (total n 
= 3,211), based on having complete available data on all PHQ-9 items. 
French- and English-speaking participants were included, though the 
majority (n = 2,913; 91%) were French-speakers. 
UK Biobank 
The UK Biobank includes a population-based cohort consisting of 
501,726 individuals aged between 40-69 years in 2006-2010, who were 
recruited through direct mailing invitations to 9.2 million National 
Health Service contact details living in reasonable proximity to one of 22 
assessment centres throughout the United Kingdom. Assessment 
included demographic, socio-economic, psychosocial, and environ-
mental factors, health status, and a range of physical measures (Sudlow 
et al., 2015). Participants entered their responses using a touch screen. 
Support was available at all times and a mouse and keyboard were 
available for those not comfortable with touchscreen computers (see 
https://biobank.ctsu.ox.ac.uk/crystal/crystal/docs/Touchscreen.pdf). 
In 2016, an online link for a mental health questionnaire including 
the PHQ-9 was sent to all UK Biobank participants with an email address 
(n = 339,092) and 46% (n = 157,367) had responded (31% of total 
cohort) (Davis & Hotopf, 2019). The UK Biobank and subsequent 
amendments including the added mental health questionnaire were 
approved by the North West Multi-centre Research Ethics Committee. 
For this study, we used a data set that was created to examine the 
genetical aspects of depression in people with diabetes and only 
included participants with white European heritage (n=487,320). Of 
those, 25,474 participants self-reported having diabetes mellitus, while 
459,727 participants self-reported never having received a diagnosis of 
diabetes. 
PHQ-9 data was available for 5,122 participants with diabetes and 
for 148,311 participants without diabetes. Among those, 4,981 partici-
pants with diabetes (97%) and 145,570 controls without diabetes (98%) 
had complete PHQ-9 data sets and were included in the current study 
(total n = 150,551). 
2.2. Measures 
Depressive symptoms. In all cohorts, the 9-item Patient Health 
Questionnaire (PHQ-9; Kroenke et al., 2001) was used to assess 
depressive symptoms. Item names, along with their frequencies across 
the three cohorts, are presented in Supplementary Table 1. Participants 
scored the items on 4-point scales ranging from 0 (“not at all”), 1 
(“several days”), 2 (“more than half of the days”), and 3 (“nearly every 
day”). The total score ranged from 0 to 27. Because in the UK Biobank 
the PHQ-9 response options ranged from 1-4, these were recoded into 
0-3. 
Demographics included age, sex of birth, education level, and ethnic 
Table 1 
Demographic variables for participants with and without diabetes by the three 
datasets (NHANES, EMHS-HID, UK Biobank).  
Variables Diabetes Control  
NHANES  
N=1,886 N=4,153 
Age, mean (sd) 61.6 (13.1) 42.1 (17.7) 
Sex, men n (%) 939 (49.7) 1,808 (43.5) 
Qualifications, n (%)   
University/College 646 (34.3) 1,087 (18.3) 
Some College 418 (22.2) 767 (18.5) 
High school diploma or GED 521 (27.6) 1,202 (28.9) 
Less than high school diploma 288 (15.3) 1,087 (26.2) 
Ethnicity, n (%)   
White 678 (35.9) 1,840 (44.3) 
Black 530 (28.1) 826 (19.9) 
Hispanic 498 (26.4) 1,005 (24.2 
Other 180 (9.5) 482 (11.6) 
PHQ-9 levels of depression severity, n (%)   
Minimal (0-4) 1,214 (64.4) 3,187 (76.7) 
Mild (5-9) 376 (19.9) 641 (15.4) 
Moderate (10-14) 165 (8.7) 209 (5.0) 
Moderately severe (15-19) 95 (5.0) 83 (2.0) 
Severe (20-27) 36 (1.9) 33 (0.8) 
Mean (sd; range) 4.4 (4.1; 0 to 
25) 




Age, mean (sd) 63.8 (7.5) 58.4 (7.5) 
Sex, men, n (%) 446 (62.8) 971 (42.0) 
Qualifications, n (%)   
University/College 515 (73.5) 1,935 (81) 
High school diploma 166 (23.7) 426 (17.9) 
Less than high school diploma 20 (2.9) 22 (0.9) 
Ethnicity White European, % 88% 93% 
PHQ-9 levels of depression severity   
Minimal (0-4) 469 (58.6) 1,477 (61.3) 
Mild (5-9) 202 (25.3) 578 (24.0) 
Moderate (10-14) 79 (9.9) 207 (8.6) 
Moderately severe (15-19) 36 (4.5) 112 (4.6) 
Severe (20-27) 14 (1.8) 37 (1.5) 
Mean (sd; range) 5.0 (5.1; 0 to 
25) 
4.7 (4.9; 0 to 
27)  
UK Biobank  
N=4,981 N=145,570 
Age, mean (sd) 59.06 (7.0) 56.3 (7.8) 
Sex, men, n (%) 3,055 (61.3) 62,665 (43.0) 
Qualifications, n (%)   
University/College degree 1,926 (39) 66,701 (46) 
College (A-levels, professional, or 
equivalent) 
1,305 (26) 34,198 (23) 
Secondary education (O-levels, CSE or 
equivalent) 
1,185 (24) 28,194 (19) 
None of the above/prefer not to say 557 (11) 10,190 (7) 
Missing 8 (0.2) 287 (0.2) 
Ethnicity White European, n (%) 4,981 (100) 145,570 (100) 
PHQ-9 levels of depression severity, n (%)   
Minimal (0-4) 3,572 (71.7) 116,205 (79.8) 
Mild (5-9) 899 (18.0) 21,271 (14.6) 
Moderate (10-14) 317 (6.4) 5,281 (3.6) 
Moderately severe (15-19) 126 (2.5) 1,878 (1.3) 
Severe (20-27) 67 (1.3) 935 (0.6) 
Mean (sd; range) 3.6 (4.5; 0 to 
27) 
2.7 (3.7; 0 to 
27) 
Note: Unweighted percentages for NHANES education level do not add to 100% 
due to missing data 
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background (for details see Table 1). 
2.3. Statistical analysis 
A confirmatory factor analysis was first conducted to determine the 
fit of the PHQ-9 one-factor and two-factor solutions in each of the three 
cohorts for participants with and without diabetes. For the two-factor 
structure, the first factor included items reflecting a cognitive-affective 
domain of depression (items 1,2,6,9) and the second factor included 
items reflecting a somatic domain of depression (items 3,4,5,7,8) 
(Galenkamp et al., 2017). To examine PHQ-9 measurement invariance 
across groups, we conducted a series of measurement invariance tests 
using multigroup confirmatory factor analysis (CFA) with the weighted 
least squares mean and variance (WLSMV) estimator to account for the 
ordinal nature of the data (Svetina, et al., 2020). Measurement invari-
ance tests are performed in a hierarchical manner, with increasingly 
stringent constraints applied to the parameters to determine if they are 
equal across groups. Measurement invariance support in each hierarchal 
level would lend strong support for the notion that the instrument is 
indeed measuring the same construct in a similar way across diabetes 
status groups. For the present study, we tested whether the one-factor 
and the two-factor structures of the PHQ-9 were invariant across 
groups of adults with diabetes and without diabetes. 
For each test, PHQ-9 items were modelled as categorical variables. 
The recommended guidelines outlined by Wu and Estabrook (2016) and 
Svetina et al. (2020) for invariance testing of ordinal data were followed. 
This approach differs from the traditional approach for measurement 
invariance using continuous outcome variables (e.g., Vandenberg and 
Lance, 2000), though is better suited for ordinal variables such as the 
PHQ-9. Three increasingly restrictive models were hierarchically 
examined to determine the degree of measurement invariance between 
participants with and without diabetes within each cohort. Configural, 
threshold, and threshold and loading invariance were tested using the 
WLSMV estimator for ordinal data. In the first step, configural invari-
ance was tested by examining whether the underlying factor structures 
are measured by the same items across those with and without diabetes, 
with an equal number and pattern of parameters across groups. In the 
second step, threshold invariance was tested by imposing an additional 
constraint on item thresholds, where these are constrained to be equal 
among diabetes groups. In a final step, threshold and loading invariance 
was tested by additionally constraining factor loadings to be equal 
among diabetes groups. An additional exploratory test was carried out to 
examine measurement invariance on the PHQ-9 across the three cohorts 
included in the present study (NHANES, EMHS-HID, and the UK Bio-
bank). Analyses were conducted using MPlus version 7.4 (Muthén and 
Muthén, 2018). 
Goodness of fit statistics were estimated for each CFA and mea-
surement invariance models and were based on standard evaluative 
criteria (Chen, 2007). While a non-statistically significant chi-square 
value is often used to indicate model fit, this value is sensitive to sam-
ple size. Given the large sample sizes of the present study, we focused on 
indicators of model fit that are less sensitive to sample size (Chen, 2007), 
although we report chi-square statistics for completeness. A Root Mean 
Square Error of Approximation (RMSEA) equal to or below .08 and a 
Comparative Fit Index (CFI) value equal to or above .90 are indicative of 
acceptable model fit. For measurement invariance testing, an additional 
set of criteria were examined to determine measurement invariance 
based on changes in CFI and RMSEA values in the increasingly stringent 
measurement invariance models. Changes in RMSEA <0.015 and 
changes in CFI <0.01 indicate support for that level of measurement 
invariance (Chen, 2007). A chi-square difference test was also con-
ducted, comparing the more stringent models with the model from the 
previous step (i.e., the thresholds only model was compared to the 
configural invariance model, and the thresholds and loadings model was 
compared to the thresholds only model), with a non-statistically sig-
nificant chi square difference test indicating measurement invariance. 
However, the chi-square difference test is also sensitive to sample size 
and therefore the focus for determining measurement invariance 
remained on changes in RMSEA and CFI. 
3. Results 
Sample characteristics are presented in Table 1. The frequency of 
responses on all PHQ-9 items, stratified by cohort, are presented in 
Supplementary Table 1. Overall, individuals with diabetes in all cohorts 
tended to report a greater severity of depressive symptoms compared to 
those without diabetes. 
Results of the CFA tests demonstrated good model fit for both the 
one-factor and the two-factor solutions (Table 2) across each cohort. 
However, there was stronger support for a two-factor structure in all 
cohorts, and particularly for the UK biobank according to the RMSEA 
value. In the one-factor solution, RMSEA was .076 for those with dia-
betes and was .074 for those without diabetes, whereas in the two-factor 
solution, RMSEA was .052 for those with diabetes and was .049 for those 
without diabetes. 
Table 3 presents the results of the measurement invariance tests per 
cohort for the one-factor solution models. We found that applying 
increasingly stringent constraints across the three levels of invariance 
testing did not significantly reduce model fit (all ΔCFI values were below 
0.01 and all ΔRMSEA values were below 0.015) and model fit was 
acceptable for the configural, thresholds only, and loadings and 
thresholds models in all three cohorts. The most stringent model, testing 
equal loadings and thresholds, demonstrated satisfactory model fit in the 
three cohorts (RMSEA = 0.063 or below and CFI = .978 or above), 
providing support for measurement invariance between groups of peo-
ple with and without diabetes using a one-factor solution. 
Table 4 presents the results of the measurement invariance tests per 
cohort for the two-factor solution models. Similarly, applying increas-
ingly stringent constrains did not significantly reduce model fit ac-
cording to the critical values (all ΔCFI values were below 0.01 and all 
ΔRMSEA values were below 0.015), and model fit for the configural, 
thresholds only, and loadings and thresholds models in all three cohorts 
was acceptable. We also found that the most stringent model, testing 
equal loadings and thresholds, was satisfactory across the three cohorts 
(RMSEA = 0.042 or below and CFI = .990 or above). Model fit indices 
and chi-square difference tests provided greater support in the models 
testing a two-factor solution compared to the models testing a one-factor 
solution. 
Finally, results indicated support for measurement invariance in the 
models comparing the PHQ-9 items in participants with diabetes across 
the three cohorts included in the present study (Table 5). Although the 
chi-square difference tests for the more stringent models were statisti-
cally significant, this was not surprising given the large sample sizes. 
Configural, equal thresholds, and equal thresholds and loadings mea-
surement invariance was supported by examining the changes in RMSEA 
and CFI values across the increasingly stringent models (all ΔCFI values 
were below 0.01 and all ΔRMSEA values were below 0.015), and model 
fit was acceptable for the one-factor and the two-factor solutions, though 
with better fitting models in with a two-factor solution (Table 5). 
4. Discussion 
The present study examined whether the PHQ-9 was measurement 
invariant across people with and without diabetes in three large inde-
pendent datasets from the USA (NHANES), Quebec, Canada (EMHS- 
HID), and the UK (UK-Biobank). The results showed that the PHQ-9 was 
measurement invariant across people with and without diabetes in each 
of the datasets. Measurement invariance was found for both the one- 
factor and the two-factor solutions of the PHQ-9. The findings suggest 
that the meaning of the PHQ-9 items is similar for people with and 
without diabetes. Thus, despite differences in the level of depression 
between people with diabetes and without diabetes, and the potential 
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overlap of some depression symptoms (e.g. trouble falling asleep, 
sleeping too much; feeling tired or having little energy; poor appetite or 
overeating) with symptoms of diabetes, these differences do not seem to 
be attributable to differences in interpretation of the PHQ-9 items. 
Comparing the diabetes samples across the three datasets also 
showed measurement invariance of the PHQ-9 despite differences in 
ethnic make-up with NHANES being a multi-ethnic cohort, the EMHS- 
HIS cohort of predominantly composed of French Canadians, and the 
UK-Biobank cohort in this study entirely composed of white Europeans. 
Our results extend those of earlier studies showing PHQ-9 measurement 
invariance across various demographic, cultural and ethnic, and patient 
groups and settings (Merz et al., 2011; Arthurs et al., 2012; Petersen 
et al., 2015; Galenkamp et al., 2017; González-Blanch et al., 2018; 
Keum et al., 2018; Miranda and Scopetta, 2018; Harry et al, 2019; 
Leung et al., 2020; Villarreal-Zegarra et al. 2019) and demonstrate the 
robustness of the PHQ-9 across groups and settings. 
It is important to note that despite measurement invariance indi-
cating that any differences between cohorts cannot be attributed to 
differences in interpretation of the PHQ-9 items, gender, socio-economic 
and cultural differences may exist between countries affecting the way 
depressive symptoms are perceived and expressed. Further research is 
needed to address this issue. 
We also examined whether the factor structure of the PHQ-9 was 
better explained by a one-factor solution or a two-factor solution with 
one factor reflecting the somatic items and the other factor the 
cognitive-affective items. The results demonstrated that both factor so-
lutions had good fit to the data, with the two-factor solution showing a 
somewhat better fit. Our results are consistent with Janssen et al. (2016) 
who also found support for both a one-factor and two-factor solutions in 
a sample of people with diabetes and with research in non-diabetes 
samples (e.g. Chilcot et al., 2013; Petersen et al., 2015; Beard et al., 
2016). While the two-factor solution seems to better fit PHQ-9 data 
across populations, the one-factor solution is more parsimonious. The 
implication for using the PHQ-9 in people with diabetes is that both 
factor structures can be used for measuring depressive symptoms, and 
factor solution can be selected according to the research or clinical 
Table 2 
Confirmatory Factor Analysis Results  
Model N Free parameters χ2 (df) χ2 p value RMSEA CFI 
NHANES 
1-factor model 
Diabetes group 1,886 36 235.47(27) <.00001 0.06 0.98 
Control group 4,153 36 398.43(27) <.00001 0.06 0.98 
2-factor model 
Diabetes group 1,886 37 158.61(26) <.00001 0.05 0.99 
Control group 4,153 37 224.51(26) <.00001 0.04 0.99 
EMHS-HID 
1-factor model 
Diabetes group 800 36 96.85 (27) <.00001 0.06 0.98 
Control group 2,411 36 315.95(27) <.00001 0.07 0.98 
2-factor model 
Diabetes group 800 37 55.02(26) 0.0008 0.04 0.99 
Control group 2,411 37 151.41(26) <.00001 0.05 0.99 
UK Biobank 
1-factor model 
Diabetes group 4,981 36 798.02 (27) <.00001 0.08 0.98 
Control group 145,570 36 21751.03 (27) <.00001 0.07 0.98 
2-factor model 
Diabetes group 4,981 37 379.12 (26) <.00001 0.05 0.99 
Control group 145,570 37 9174.46 (26) <.00001 0.05 0.99 
Note. The two-factor models including a somatic symptom cluster (items 3,4,5,7,8) and a cognitive-affective symptom cluster (items 1,2,6,9). 
Table 3 
Results of 1-factor invariance test  
Model Free para- 
meters 




χ2 control RMSEA CFI Reference 
model 





1.Configural 72 633.46 
(54) 










<.00001 248.16 395.89 0.05 0.98 2 -0.005 0.002 13.67(8) 0.0909 
EMHS-HID 
1.Configural 72 408.03 
(54) 










<.00001 124.77 302.99 0.06 0.98 2 -0.005 0.001 24.33 (8) 0.0020 
UK Biobank 
1.Configural 72 23029.77 
(54) 










<.00001 853.29 21061.00 0.06 0.98 2 -0.008 0.003 36.08(8) <0.0001  
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needs. The two-factor solution can provide additional information on 
the cognitive and somatic domains of depression in people with dia-
betes, whereas the one-factor solution can be used to screen for 
depression, with recommended cut-off scores that can be applied to the 
total scale summary score to indicate potentially high levels of depres-
sion (Spitzer et al., 2001). 
The results of the current study should be interpreted against its 
limitations. First, the three datasets did not include information to 
distinguish between types of diabetes, although the cohorts were likely 
predominantly comprised of people with type 2 diabetes. For example, 
using treatment-based algorithms Mosslemi et al. (2020) showed that 
94% of NHANES participants had type 2 diabetes, while Thomas et al. 
(Thomas et al., 2018) estimated that 4% of white Europeans with dia-
betes in the UK-Biobank had type 1 diabetes based on genetic risk scores. 
Further studies are needed to establish whether the factor structure of 
the PHQ-9 and measurement invariance differs between the two types of 
diabetes. Second, the study was based on data from three culturally 
closely linked western countries (USA; Quebec, Canada; UK) and, 
despite the availability of the PHQ-9 in many countries and languages 
across the globe, the results may not be generalisable to other countries, 
cultures, and languages. While previous research has shown that the 
PHQ-9 is measurement invariant between different ethnic groups in the 
Netherlands (Baas et al., 2011; Galenkamp et al., 2017), Germans and 
native Russians living in Germany (Hirsch et al., 2013) and across sex, 
race/ethnicity and education within the NHANES data set 2015-2016 
(Patel et al., 2019), only partial measurement invariance was found 
between Chinese and German student samples (Zhou et al., 2020). 
Further research is needed to examine whether the results can be 
extended to other cultures and languages. Third, two of the study sam-
ples (EMHS-HID and the UK Biobank) had a limited age range and 
consisted only of middle-aged participants. However, despite the dif-
ferences in age range between these two cohorts and the NHANES 
cohort, the PHQ-9 showed invariance across the three cohorts. More-
over, our findings are in line with those of González-Blanch et al. (2018) 
who found measurement invariance of the PHQ-9 across younger (20-39 
years old) and older (40-65 years old) adults in primary care patients in 
Spain. Fourth, the NHANES and UK Biobank assessed diabetes status by 
self-report, whereas the EMHS-HID cohort included a combination of 
self-report and HbA1c in the diabetes assessment. However, given that 
measurement invariance was found in all three cohorts, the nature of the 
Table 4 
Results of 2-factor invariance test  
Model Free para- 
meters 






RMSEA CFI Reference 
model 





1.Configural 74 383.45 
(52) 
<.00001 157.37 226.08 0.046 0.99 - - - - - 
2.Equal thresholds 65 414.71 
(61) 





<.00001 171.83 230.02 0.040 0.99 2 -0.004 0.00 11.61(7) 0.1142 
EMHS-HID 
1.Configural 74 205.57 
(52) 
<.00001 54.52 151.05 0.043 0.99 - - - - - 
2.Equal thresholds 65 223.48 
(61) 





<.00001 84.67 155.58 0.040 0.99 2 -0.001 -.001 23.75(7) 0.0013 
UK Biobank 
1.Configural 74 9729.75 
(52) 
<.00001 369.37 9360.38 0.050 0.99 - - - - - 
2.Equal thresholds 65 10214.52 
(61) 





<.00001 417.95 8866.80 0.042 0.99 2 -0.005 0.001 37.48(7) <0.0001  
Table 5 
Results of invariance tests comparing diabetes groups from EMHS, NHANES and UK Biobank Follow-up data (N = 7,667, EMHS = 800, NHANES = 1,886, UK Biobank 










χ2UKB RMSEA CFI Reference 
model 





1.Configural 108 1085.69 
(81) 











<.0001 131.44 272.24 740.31 0.06 0.98 2 -0.007 0.001 61.85(16) <0.0001 
2-factor model 
1.Configural 111 570.82 
(78) 











<.00001 90.40 202.91 369.62 0.04 0.99 2 -0.003 0.00 58.93(14) <0.0001 
Indications for change in goodness of fit statistics: ΔCFI <0.01 and ΔRMSEA <0.015 indicating support for that level of invariance. 
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diabetes assessment, in this study, did not seem to impact the overall 
findings. Fifth, there were differences in the way the PHQ-9 was 
administered between the cohorts. In NHANES and EMHS-HID, trained 
interviewers were used while in the UK-Biobank participants entered 
their responses via a touchscreen. However, despite these differences, 
the PHQ-9 was measurement invariant between the cohorts for people 
with diabetes. Finally, participants in the EMHS-HID with high depres-
sive symptoms were oversampled resulting in higher mean levels of 
depression compared to the NHANES and UK Biobank cohorts. 
It can be concluded that the meaning of the PHQ-9 items is similar for 
people with and without diabetes. Both a two-factor solution and the 
one-factor solutions show good fit to the data suggesting that both factor 
structures can be used for measuring depressive symptoms among 
people with diabetes, and factor solution can be selected based on 
research or clinical need. Comparisons of PHQ-9 scores between these 
two groups are likely to be meaningful, whether presented as a total 
score or as sub-scores of somatic and/or cognitive-affective items. 
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González-Blanch, C., Medrano, L.A., Muñoz-Navarro, R., Ruíz-Rodríguez, P., Moriana, J. 
A., Limonero, J.T., Cano-Vindel, A., 2018. Factor structure and measurement 
invariance across various demographic groups and over time for the PHQ-9 in 
primary care patients in Spain. PLoS One 13 (2), e0193356. https://doi.org/ 
10.1371/journal.pone.0193356. 
Hansson, M., Chotai, J., Nordstöm, A., Bodlund, O., 2009. Comparison of two self-rating 
scales to detect depression: HADS and PHQ-9. Br. J. Gen. Pract. 59 (566), 
e283–e288. https://doi.org/10.3399/bjgp09X454070. 
Harding, K.A., Pushpanathan, M.E., Whitworth, S.R., Nanthakumar, S., Bucks, R.S., 
Skinner, T.C., 2019. Depression prevalence in Type 2 diabetes is not related to 
diabetes–depression symptom overlap but is related to symptom dimensions within 
patient self-report measures: a meta-analysis. Diabet. Med. 36 (12), 1600–1611. 
Harry, M.L., Waring, S.C., 2019. The measurement invariance of the Patient Health 
Questionnaire-9 for American Indian adults. J. Affect. Disord. 254, 59–68. https:// 
doi.org/10.1016/j.jad.2019.05.017. 
Hirsch, O., Donner-Banzhoff, N., Bachmann, V., 2013. Measurement equivalence of four 
psychological questionnaires in native-born Germans, Russian-speaking immigrants, 
and native-born Russians. J. Transcult. Nurs. 24 (3), 225–235. https://doi.org/ 
10.1177/1043659613482003. 
Huang, F.Y., Chung, H., Kroenke, K., Delucchi, K.L., Spitzer, R.L., 2006. Using the Patient 
Health Questionnaire-9 to measure depression among racially and ethnically diverse 
primary care patients. J. Gen. Intern. Med. 21 (6), 547–552. https://doi.org/ 
10.1111/j.1525-1497.2006.00409.x. 
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